WallStSmart

Becton Dickinson and Company (BDX)vsStevanato Group SpA (STVN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 1748% more annual revenue ($21.92B vs $1.19B). STVN leads profitability with a 11.8% profit margin vs 8.0%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

STVN

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 6.5Value: 4.7Quality: 6.3
Piotroski: 4/9Altman Z: 2.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued
STVNSignificantly Overvalued (-262.8%)

Margin of Safety

-262.8%

Fair Value

$4.30

Current Price

$14.18

$9.88 premium

UndervaluedFair: $4.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

STVN2 strengths · Avg: 8.0/10
Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

STVN3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

EPS GrowthGrowth
0.3%4/10

0.3% earnings growth

PEG RatioValuation
3.572/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : STVN

The strongest argument for STVN centers on Price/Book, Operating Margin.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : STVN

The primary concerns for STVN are Revenue Growth, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

STVN carries more volatility with a beta of 0.57 — expect wider price swings.

STVN is growing revenue faster at 4.8% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.

Want to dig deeper into these stocks?